Search

Intellia Therapeutics Inc

Suletud

SektorTervishoid

12.86 -1.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.75

Max

12.96

Põhinäitajad

By Trading Economics

Sissetulek

-107M

-203M

Müük

-7.4M

7.7M

Aktsiakasum

-0.8

Kasumimarginaal

-2,648.714

Töötajad

377

EBITDA

-11M

-105M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+59.42% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

255M

1.8B

Eelmine avamishind

14.69

Eelmine sulgemishind

12.86

Uudiste sentiment

By Acuity

35%

65%

87 / 340 Pingereas Healthcare

Intellia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. aug 2026, 20:08 UTC

Intellia Therapeutics shares are lower today, continuing a recent downward trend amid rising U.S. Treasury yields and broader market weakness. No specific news was identified.

27. aug 2026, 23:41 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from an earlier dip and surpassing their 20-day moving average. No specific news was identified.

26. aug 2026, 23:11 UTC

Intellia Therapeutics Inc is higher in after-market hours, reflecting broader market gains. The asset remains above its 20-day moving average and near its one-month range.

25. aug 2026, 20:09 UTC

News
Correlated Moves

Citizens reiterated its Market Outperform rating on Intellia Therapeutics and maintained a $30 price target, contributing to positive sentiment and higher shares.

24. aug 2026, 23:01 UTC

Intellia Therapeutics shares declined after-market, moving lower from Monday's close. The stock remains above its 20-day moving average and near its one-month range.

21. aug 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

20. aug 2026, 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19. aug 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17. aug 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14. aug 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11. aug 2026, 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10. aug 2026, 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7. aug 2026, 19:26 UTC

News
Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6. aug 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4. aug 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3. aug 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31. juuli 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30. juuli 2026, 17:57 UTC

Correlated Moves
News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29. juuli 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28. juuli 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27. juuli 2026, 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25. juuli 2026, 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24. juuli 2026, 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23. juuli 2026, 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22. juuli 2026, 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

21. juuli 2026, 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

20. juuli 2026, 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Võrdlus sarnastega

Hinnamuutus

Intellia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

59.42% tõus

12 kuu keskmine prognoos

Keskmine 20.9 USD  59.42%

Kõrge 49 USD

Madal 9 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Intellia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

6

Osta

4

Hoia

2

Müü

Sentiment

By Acuity

87 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat